Safe is defined by the U.S. Food and Drug Administration (FDA) as: “a reasonable certainty in the minds of competent scientists that the substance is not harmful under the intended conditions of use”.
The GRAS pathway can be a valuable approach to achieve regulatory compliance for new and innovative ingredients. FDA requires specific information and a specific format for a GRAS dossier and RNI can provide the expertise you need to understand the GRAS process.
RNI can also walk you through the NDI notification process to help determine which pathway is most appropriate for your specific ingredient.
Specific ingredient reviews to determine if a GRAS or NDI notification is needed
Regulatory framework for GRAS and NDIN pathways
Strategic assessment of unique ingredients to determine the best approach for regulatory compliance
Analysis of your safety data to identify potential gaps
Full GRAS dossier for a notified (submitted to FDA) or an independent (self-affirmed) GRAS